NASHUA, N.H., Dec. 3 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD),
which designs, develops and markets Computer Aided Detection (CAD) imaging
technology and systems for the early detection of breast cancer, today
announced that the Company will host an investor conference call on Tuesday,
December 9, 2003, at 10:00 am EST, to discuss the acquisition of CADx,
observations regarding the 2003 RSNA meeting, and the current outlook for the
balance of 2003 and next year. W. Scott Parr, CEO and President of iCAD and
Dr. Steven Rogers, former President and Founder of CADx and Qualia Computing,
Inc. and now Chief Scientific Officer of iCAD, Inc., will be the moderators of
the call.
Shareholders and other interested parties may participate in the
conference call by dialing 800-915-4836 (international/local participants dial
973-317-5319) a few minutes before 10:00 a.m. EST on December 9, 2003. The
call will also be broadcast live on the Internet at
http://www.firstcallevents.com/service/ajwz394696567gf12.html . A replay of
the conference call will be available two hours after its completion, from
December 9, 2003 until December 16, 2003 by dialing 800-428-6051
(international/local participants dial 973-709-2089) and entering conference
ID number 317671. The call will also be archived for 90 days at
http://www.firstcallevents.com/service/ajwz394696567gf12.html .
About iCAD, Inc.
iCAD, the only vertically integrated company in the CAD industry, also
manufactures medical film digitizers for a variety of medical imaging and
other applications. The Company currently has 117 employees, is headquartered
in Nashua, New Hampshire, and operates field locations in Tampa, Florida; San
Mateo, California; Beavercreek, Ohio; and several other cities. Its common
stock is listed on The Nasdaq Stock Market under the symbol "ICAD." More
information on iCAD's products can be found at http://www.cadxsystems.com and at
http://www.icadmed.com .
Certain statements contained in this News Release constitute "forward-
looking" statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve a number of known
and unknown risks, uncertainties and other factors that may cause actual
results to differ materially from such forward-looking statements. Such risks
include, but are not limited to, uncertainties associated with litigation
and/or government regulation, changes in Medicare reimbursement policies,
competitive factors, and other risks that are detailed in the Company's
periodic filings with the Securities and Exchange Commission. The words
"believe," "demonstrate," "intend," "expect," "estimate," "anticipate,"
"likely" and similar expressions identify forward-looking statements. Readers
are cautioned to avoid placing undue reliance on such forward-looking
statements, which speak only as of the date the statements were made.
For more information on iCAD, Inc. please contact, RJ Falkner & Company, Inc.,
Investor Relations Counsel, at (800) 377-9893 or via email at
info@rjfalkner.com
SOURCE iCAD, Inc.
 back to top
Related links:
http://www.icadmed.com
Audio:http://www.firstcallevents.com/service/ajwz394696567gf12.html
CONTACT:
RJ Falkner & Company, Inc., Investor
Relations Counsel, +1-800-377-9893, info@rjfalkner.com, for iCAD,
Inc.
|
